Navigation Links
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
Date:9/24/2008

f clinical data at the European Society of Cardiologists by GlaxoSmithKline on the effect of their selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor, darapladib, on a secondary biological outcome while having no effect on inflammation or LDL-C, provides encouraging validation of the anatomical importance of reducing PLA2 activity in a cardiovascular population," said Dr. Robert S. Rosenson, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research at the University of Michigan. "The on-going FRANCIS trial with varespladib, which is designed to evaluate and repeat the results of previous clinical data from PLASMA and PLASMA2 in an ACS population, should provide additional data on an already validated predictor of cardiovascular risk (LDL-C) coupled with reductions in PLA2."

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, clinically meaningful and statistically significant reductions in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.

Presently, the company is conducting the five hundred patient FRANCIS trial (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) to assess the impact of oral varespladib on known biological markers of cardiovascular risk in ACS patients with elevated LDL and CRP. FRANCIS will also provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the six-month trial.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and he
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
7. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
8. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
10. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/10/2014)... to bump up their grade point averages during college, ... a library or study hall, but in a gym. ... who were members of the recreational sports and fitness ... years had higher GPAs than those who weren,t. ... stayed in school longer. An increase of 3.5 percent ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... that are just as tempting as full-fat equivalents ... fresh insights into how proteins can replace fats ... Funded by the Engineering and Physical Sciences Research ... the University of Edinburgh has produced modified proteins ... closely mimic the behaviour of fats during food ...
(Date:7/9/2014)... episodes of low back pain are not linked to ... direction and precipitation. Findings published in Arthritis Care ... of Rheumatology (ACR), indicate that the risk of low ... wind gusts, but was not clinically significant. , ... experiences low back pain at some point in their ...
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
Breaking Medicine News(10 mins):Health News:Want a higher GPA in college? Join a gym 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2
... and lack of proper sleep could be threatening thousands ... warns Heart and Stroke Foundation researcher Dr. Brian McCrindle, ... in Toronto. "Sleep disorders in kids are on ... other increasing cardiovascular risk factors such as overweight and ...
... 25, 2010 Young children who consume substantial amounts ... with fluoridated water or by swallowing fluoride toothpaste have ... to research published in the October issue of The ... supported by the National Institute of Dental and Craniofacial ...
... fear some of it unjustified are common among ... as MRSA, according to the results of a small study ... timely, detailed and simple information, the researchers add. ... Pediatrics , underscore the need for healthcare staff to do ...
... Reporter , MONDAY, Oct. 25 (HealthDay News) -- Why is ... the next day one person ends up feeling more tired ... in their genes, a new study suggests. Researchers at ... individuals who test positive for a common gene variant are ...
... Randy Dotinga HealthDay Reporter , MONDAY, Oct. 25 ... -- to be honest about their drug use, a new ... extent of drug use, but this new research finds that ... for drugs or they,re told the results will be confidential. ...
... treated with a combination of hormone therapy and radiation have ... do not receive radiation, according to interim results of the ... session, November 1, 2010, at the 52nd Annual Meeting of ... 1995 to 2005, 1,205 men with high-risk prostate cancer in ...
Cached Medicine News:Health News:Cardiac wakeup call for Canadian kids 2Health News:Cardiac wakeup call for Canadian kids 3Health News:Substantial consumption of fluoride increases chance of mild fluorosis 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 3Health News:How You Handle Lack of Sleep May Be in Your Genes 2Health News:How You Handle Lack of Sleep May Be in Your Genes 3Health News:Teens, Parents Often Lie About Illicit Drug Use 2Health News:Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances 2
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... distances with high Numerical Apertures, these objectives ... aberrations throughout the visible spectrum from violet ... the entire 25mm field of view. They ... reproduction, plus resolving power at the theoretical ...
Medicine Products: